Mp0533, A Cd3-Engaging Darpin, In R/R Aml Or Mds/Aml: Preliminary Results Of A Phase I/Iia Trial

MP0533, a CD3-engaging DARPin, in R/R AML or MDS/AML: preliminary results of a Phase I/IIa trial

VJHemOnc – Video Journal of Hematology & HemOnc

Phase I study of CD123 NK cell engager SAR443579 in R/R AML, B-ALL or HR-MDS

VJHemOnc – Video Journal of Hematology & HemOnc

Harnessing T-cells in acute leukemia and an anti-CD33/CD3 BiTE antibody

VJHemOnc – Video Journal of Hematology & HemOnc

IL3-zetakine coupled to a CD33 costimulatory receptor as a dual-targeting CAR approach in AML

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Ravandi on Targeting CD33 in Relapsed/Refractory AML

Older patients with AML benefit greatly from SGN-CD33 and HMA therapy combo

Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients

CD47 antibodies for the treatment of AML and MDS: where is the field moving?

VJHemOnc – Video Journal of Hematology & HemOnc

Bunctional PD-1 x αCD3 x αCD33 CiTE for AML

VJHemOnc – Video Journal of Hematology & HemOnc

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

Is treatment in the spine common for treating pediatric AML? #AML

HealthTree University for Blood Cancers

Acute Myeloid Leukemia -- Pre-Treatment

DARIC33 CAR T-cells in AML

Assessing FLT3-ITD-specific MRD clearance using a PCR-NGS assay in the QuANTUM-First trial

VJHemOnc – Video Journal of Hematology & HemOnc

The potential of menin inhibitors in specific molecular subsets of AML & ALL

VJHemOnc – Video Journal of Hematology & HemOnc

What to do and expect immediately after diagnosis

Patient Power Europe

Chemoresistance and residual disease promoted by DNMT3A R882 in AML

A Look at Ongoing Acute Myeloid Leukemia Phase III Trials

Patient Empowerment Network

Phase I trial of BI 764532, a T-cell engager for DLL3-positive NEC and SCLC

Determining the Treatment Options for t-AML

Targeted Oncology